Anne H Kallioniemi

List of Publications by Year
in descending order

104 papers	12,096 citations	44069 48 h-index	33894 99 g-index
107 all docs	107 docs citations	107 times ranked	11969 citing authors

#	Article	IF	Citations
1	Novel ZNF414 activity characterized by integrative analysis of ChIP-exo, ATAC-seq and RNA-seq data. Biochimica Et Biophysica Acta - Gene Regulatory Mechanisms, 2022, 1865, 194811.	1.9	1
2	A search for modifying genetic factors in CHEK2:c.1100delC breast cancer patients. Scientific Reports, 2021, 11, 14763.	3.3	3
3	Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Ovarian Cancer Cells In Vitro. Anticancer Research, 2020, 40, 3129-3138.	1.1	11
4	Recurrent moderateâ€risk mutations in Finnish breast and ovarian cancer patients. International Journal of Cancer, 2019, 145, 2692-2700.	5.1	19
5	Depletion of nuclear import protein karyopherin alpha 7 (KPNA7) induces mitotic defects and deformation of nuclei in cancer cells. BMC Cancer, 2018, 18, 325.	2.6	14
6	Transcription factorsâ€"Intricate players of the bone morphogenetic protein signaling pathway. Genes Chromosomes and Cancer, 2018, 57, 3-11.	2.8	8
7	Clinicopathological and prognostic correlations of HER3 expression and its degradation regulators, NEDD4â€"1 and NRDP1, in primary breast cancer. BMC Cancer, 2018, 18, 1045.	2.6	20
8	Wound healing of human embryonic stem cell-derived retinal pigment epithelial cells is affected by maturation stage. BioMedical Engineering OnLine, 2018, 17, 102.	2.7	4
9	PLA2G7 associates with hormone receptor negativity in clinical breast cancer samples and regulates epithelialâ€mesenchymal transition in cultured breast cancer cells. Journal of Pathology: Clinical Research, 2017, 3, 123-138.	3.0	20
10	Case-control analysis of truncating mutations in DNA damage response genes connects TEX15 and FANCD2 with hereditary breast cancer susceptibility. Scientific Reports, 2017, 7, 681.	3.3	20
11	FANCM mutation c.5791C>T is a risk factor for triple-negative breast cancer in the Finnish population. Breast Cancer Research and Treatment, 2017, 166, 217-226.	2.5	26
12	Search for KPNA7 cargo proteins in human cells reveals MVP and ZNF414 as novel regulators of cancer cell growth. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 211-219.	3.8	13
13	Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families. BMC Cancer, 2017, 17, 496.	2.6	7
14	Paclitaxel, Carboplatin and 1,25-D3 Inhibit Proliferation of Endometrial Cancer Cells In Vitro. Anticancer Research, 2017, 37, 6575-6581.	1.1	8
15	Bone morphogenetic protein 4 regulates micro<scp>RNA</scp> expression in breast cancer cell lines in diverse fashion. Genes Chromosomes and Cancer, 2016, 55, 227-236.	2.8	11
16	FANCM c.5101C>T mutation associates with breast cancer survival and treatment outcome. International Journal of Cancer, 2016, 139, 2760-2770.	5.1	13
17	The impact of bone morphogenetic protein 4 (BMP4) on breast cancer metastasis in a mouse xenograft model. Cancer Letters, 2016, 375, 238-244.	7.2	22
18	RAD51B in Familial Breast Cancer. PLoS ONE, 2016, 11, e0153788.	2.5	26

#	Article	IF	Citations
19	Effects of Cytokine Activation and Oxidative Stress on the Function of the Human Embryonic Stem Cellâ€“Derived Retinal Pigment Epithelial Cells. , 2015, 56, 6265.		22
20	KPNA7, a nuclear transport receptor, promotes malignant properties of pancreatic cancer cells in vitro. Experimental Cell Research, 2014, 322, 159-167.	2.6	21
21	Evaluation of the RHINO gene for breast cancer predisposition in Finnish breast cancer families. Breast Cancer Research and Treatment, 2014, 144, 437-441.	2.5	1
22	Exome sequencing identifies FANCM as a susceptibility gene for triple-negative breast cancer. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15172-15177.	7.1	162
23	Breast-Cancer Risk in Families with Mutations in PALB2. New England Journal of Medicine, 2014, 371, 497-506.	27.0	745
24	Loss of CADM1 expression is associated with poor prognosis and brain metastasis in breast cancer patients. Oncotarget, 2014, 5, 3076-3087.	1.8	35
25	BMP4 inhibits the proliferation of breast cancer cells and induces an MMP-dependent migratory phenotype in MDA-MB-231 cells in 3D environment. BMC Cancer, 2013, 13, 429.	2.6	51
26	The diverse role of miRâ€31 in regulating cancer associated phenotypes. Genes Chromosomes and Cancer, 2013, 52, 1103-1113.	2.8	75
27	Bone morphogenetic protein 4 expression in multiple normal and tumor tissues reveals its importance beyond development. Modern Pathology, 2013, 26, 10-21.	5.5	50
28	HOXB13 G84E Mutation in Finland: Population-Based Analysis of Prostate, Breast, and Colorectal Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 452-460.	2.5	75
29	The expression patterns of gremlin 1 and noggin in normal adult and tumor tissues. International Journal of Clinical and Experimental Pathology, 2013, 6, 1400-8.	0.5	22
30	Rare Copy Number Variants Observed in Hereditary Breast Cancer Cases Disrupt Genes in Estrogen Signaling and TP53 Tumor Suppression Network. PLoS Genetics, 2012, 8, e1002734.	3.5	28
31	Breast Cancerâ€“Associated Abraxas Mutation Disrupts Nuclear Localization and DNA Damage Response Functions. Science Translational Medicine, 2012, 4, 122ra23.	12.4	54
32	A Finnish founder mutation inRAD51D: analysis in breast, ovarian, prostate, and colorectal cancer: Table 1. Journal of Medical Genetics, 2012, 49, 429-432.	3.2	41
33	The HOXB7 protein renders breast cancer cells resistant to tamoxifen through activation of the EGFR pathway. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 2736-2741.	7.1	95
34	Bone morphogenetic protein 4â€”a fascinating regulator of cancer cell behavior. Cancer Genetics, 2012, 205, 267-277.	0.4	81
35	Both inhibition and enhanced expression of miRâ€31 lead to reduced migration and invasion of pancreatic cancer cells. Genes Chromosomes and Cancer, 2012, 51, 557-568.	2.8	32
36	Characterization of Non-Specific Cytotoxic Cell Receptor Protein 1: A New Member of the Lectin-Type Subfamily of F-Box Proteins. PLoS ONE, 2011, 6, e27152.	2.5	24

#	Article	IF	Citations
37	Bone morphogenetic protein â˜4 and â˜5 in pancreatic cancerâ€"Novel bidirectional players. Experimental Cell Research, 2011, 317, 2136-2146.	2.6	42
38	Analysis of BMP4 and BMP7 signaling in breast cancer cells unveils time-dependent transcription patterns and highlights a common synexpression group of genes. BMC Medical Genomics, 2011, 4, 80.	1.5	22
39	MED29, a component of the mediator complex, possesses both oncogenic and tumor suppressive characteristics in pancreatic cancer. International Journal of Cancer, 2011, 129, 2553-2565.	5.1	18
40	RAD51C is a susceptibility gene for ovarian cancer. Human Molecular Genetics, 2011, 20, 3278-3288.	2.9	124
41	Parallel inhibition of cell growth and induction of cell migration and invasion in breast cancer cells by bone morphogenetic protein 4. Breast Cancer Research and Treatment, 2010, 124, 377-386.	2.5	68
42	Array-based gene expression, CGH and tissue data defines a 12q24 gain in neuroblastic tumors with prognostic implication. BMC Cancer, 2010, 10, 181.	2.6	24
43	19q13 amplification is associated with high grade and stage in pancreatic cancer. Genes Chromosomes and Cancer, 2010, 49, 569-575.	2.8	25
44	Bone morphogenetic proteins in breast cancer: dual role in tumourigenesis?. Endocrine-Related Cancer, 2010, 17, R123-R139.	3.1	99
45	DNA Copy Number Analysis on Tissue Microarrays. Methods in Molecular Biology, 2010, 664, 127-134.	0.9	6
46	Characterization of the 7q21â€q22 amplicon identifies ARPC1A, a subunit of the Arp2/3 complex, as a regulator of cell migration and invasion in pancreatic cancer. Genes Chromosomes and Cancer, 2009, 48, 330-339.	2.8	44
47	BMP7 influences proliferation, migration, and invasion of breast cancer cells. Cancer Letters, 2009, 275, 35-43.	7.2	102
48	CGH microarrays and cancer. Current Opinion in Biotechnology, 2008, 19, 36-40.	6.6	107
49	NAD(P)H:quinone oxidoreductase 1 NQO1*2 genotype (P187S) is a strong prognostic and predictive factor in breast cancer. Nature Genetics, 2008, 40, 844-853.	21.4	181
50	Deciphering downstream gene targets of PI3K/mTOR/p70S6K pathway in breast cancer. BMC Genomics, 2008, 9, 348.	2.8	75
51	PPM1D silencing by RNA interference inhibits proliferation and induces apoptosis in breast cancer cell lines with wild-type p53. Cancer Genetics and Cytogenetics, 2008, 182, 33-39.	1.0	42
52	Hypermethylated MAL gene â€" a silent marker of early colon tumorigenesis. Journal of Translational Medicine, 2008, 6, 13.	4.4	48
53	Identification of differentially expressed genes after PPM1D silencing in breast cancer. Cancer Letters, 2008, 259, 61-70.	7.2	28
54	Penetrance Analysis of the PALB2 c.1592delT Founder Mutation. Clinical Cancer Research, 2008, 14, 4667-4671.	7.0	90

#	Article	IF	Citations
55	Intersex-like (IXL) Is a Cell Survival Regulator in Pancreatic Cancer with 19q13 Amplification. Cancer Research, 2007, 67, 1943-1949.	0.9	68
56	Mutations in the BRCA2 interacting DSS1 are not a risk factor for male breast cancer. International Journal of Cancer, 2007, 120, 444-446.	5.1	4
57	A recurrent mutation in PALB2 in Finnish cancer families. Nature, 2007, 446, 316-319.	27.8	402
58	A comprehensive expression survey of bone morphogenetic proteins in breast cancer highlights the importance of BMP4 and BMP7. Breast Cancer Research and Treatment, 2007, 103, 239-246.	2.5	106
59	The serine-threonine protein phosphatase PPM1D is frequently activated through amplification in aggressive primary breast tumours. Breast Cancer Research and Treatment, 2006, 95, 257-263.	2.5	89
60	Large genomic BRCA2 rearrangements and male breast cancer. Cancer Detection and Prevention, 2006, 30, 530-534.	2.1	21
61	Bone morphogenetic protein 7 is widely overexpressed in primary breast cancer. Genes Chromosomes and Cancer, 2006, 45, 411-419.	2.8	67
62	Pancreatic adenocarcinomaâ€"Genetic portrait from chromosomes to microarrays. Genes Chromosomes and Cancer, 2006, 45, 721-730.	2.8	50
63	Search for large genomic alterations of the BRCA1 gene in a Finnish population. Cancer Genetics and Cytogenetics, 2005, 163, 57-61.	1.0	10
64	CDK4 is a probable target gene in a novel amplicon at 12q13.3â€"q14.1 in lung cancer. Genes Chromosomes and Cancer, 2005, 42, 193-199.	2.8	76
65	Immunohistochemical Expression of DNA Repair Proteins in Familial Breast Cancer DifferentiateBRCA2-Associated Tumors. Journal of Clinical Oncology, 2005, 23, 7503-7511.	1.6	70
66	Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene, 2004, 23, 1010-1013.	5.9	59
67	Frequent amplification and overexpression of CCND1 in male breast cancer. International Journal of Cancer, 2004, 111, 968-971.	5.1	26
68	A strategy for identifying putative causes of gene expression variation in human cancers. Journal of the Franklin Institute, 2004, 341, 77-88.	3.4	21
69	High-Resolution Genomic and Expression Profiling Reveals 105 Putative Amplification Target Genes in Pancreatic Cancer. Neoplasia, 2004, 6, 432-439.	5.3	104
70	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. Neoplasia, 2004, 6, 240-247.	5.3	110
71	High-Resolution Analysis of Gene Copy Number Alterations in Human Prostate Cancer Using CGH on cDNA Microarrays: Impact of Copy Number on Gene Expression. Neoplasia, 2004, 6, 240-247.	5.3	62
72	Title is missing!. Machine Learning, 2003, 52, 45-66.	5.4	44

#	Article	IF	Citations
73	Amplification of a 280-Kilobase Core Region at the ERBB2 Locus Leads to Activation of Two Hypothetical Proteins in Breast Cancer. American Journal of Pathology, 2003, 163, 1979-1984.	3.8	90
74	Topoisomerase-IÎ± Is Upregulated in Malignant Peripheral Nerve Sheath Tumors and Associated With Clinical Outcome. Journal of Clinical Oncology, 2003, 21, 4586-4591.	1.6	74
75	CGH-Plotter: MATLAB toolbox for CGH-data analysis. Bioinformatics, 2003, 19, 1714-1715.	4.1	98
76	Molecular Signatures of Breast Cancer â€" Predicting the Future. New England Journal of Medicine, 2002, 347, 2067-2068.	27.0	26
77	High-Throughput Copy Number Analysis of 17q23 in 3520 Tissue Specimens by Fluorescence in Situ Hybridization to Tissue Microarrays. American Journal of Pathology, 2002, 161, 73-79.	3.8	66
78	Cloning of BCAS3 (17q23) and BCAS4 (20q13) genes that undergo amplification, overexpression, and fusion in breast cancerâ€. Genes Chromosomes and Cancer, 2002, 35, 311-317.	2.8	100
79	Frequent amplification of 8q24, 11q, 17q, and 20qâ€specific genes in pancreatic cancer. Genes Chromosomes and Cancer, 2002, 35, 353-358.	2.8	148
80	Clinical and functional target validation using tissue and cell microarrays. Current Opinion in Chemical Biology, 2002, 6, 97-101.	6.1	41
81	Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity. Nature Genetics, 2002, 31, 210-215.	21.4	410
82	Impact of DNA amplification on gene expression patterns in breast cancer. Cancer Research, 2002, 62, 6240-5.	0.9	352
83	Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry, 2001, 45, 83-86.	1.8	60
84	From chromosomal alterations to target genes for therapy: integrating cytogenetic and functional genomic views of the breast cancer genome. Seminars in Cancer Biology, 2001, 11, 395-401.	9.6	22
85	Novel findings in gene expression detected in human osteosarcoma by cDNA microarray. Cancer Genetics and Cytogenetics, 2000, 123, 128-132.	1.0	60
86	Detecting Activation of Ribosomal Protein S6 Kinase by Complementary DNA and Tissue Microarray Analysis. Journal of the National Cancer Institute, 2000, 92, 1252-1259.	6.3	251
87	Concomitant gastrin and ERBB2 gene amplifications at 17q12-q21 in the intestinal type of gastric cancer. , 1999, 24, 24-29.		33
88	Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes and Cancer, 1998, 21, 177-184.	2.8	313
89	Genetic alterations in prostate cancer cell lines detected by comparative genomic hybridization. Cancer Genetics and Cytogenetics, 1998, 101, 53-57.	1.0	88
90	Molecular cytogenetics of primary breast cancer by CGH. , 1998, 21, 177.		2

#	Article	IF	Citations
91	Molecular cytogenetics of primary breast cancer by CGH. Genes Chromosomes and Cancer, 1998, 21, 177-184.	2.8	7
92	Genome screening by comparative genomic hybridization. Trends in Genetics, 1997, 13, 405-409.	6.7	272
93	Increased copy number at 17q22-q24 by CGH in breast cancer is due to high-level amplification of two separate regions. , 1997, 20, 372-376.		74
94	Genetic alterations in lobular breast cancer by comparative genomic hybridization. , 1997, 74, 513-517.		139
95	Genetic alterations in lobular breast cancer by comparative genomic hybridization. International Journal of Cancer, 1997, 74, 513-517.	5.1	3
96	Gene Copy Number Analysis by Fluorescencein SituHybridization and Comparative Genomic Hybridization. Methods, 1996, 9, 113-121.	3.8	44
97	Amplifications of oncogeneerbB-2 and chromosome 20q in breast cancer determined by differentially competitive polymerase chain reaction. Breast Cancer Research and Treatment, 1996, 40, 271-281.	2.5	10
98	Identification of gains and losses of DNA sequences in primary bladder cancer by comparative genomic hybridization. Genes Chromosomes and Cancer, 1995, 12, 213-219.	2.8	198
99	Computer image analysis of comparative genomic hybridization. Cytometry, 1995, 19, 10-26.	1.8	250
100	A physical map of chromosome 20 established using fluorescence in situ hybridization and digital image analysis. Genomics, 1995, 26, 134-137.	2.9	50
101	Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes and Cancer, 1994, 10, 231-243.	2.8	1,215
102	Improved technique for analysis of formalin-fixed, paraffin-embedded tumors by fluorescence in situ hybridization. Cytometry, 1994, 16, 93-99.	1.8	116
103	Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors. Science, 1992, 258, 818-821.	12.6	3,065
104	Molecular cytogenetics: Diagnosis and prognostic assessment. Current Opinion in Biotechnology, 1992, 3, 623-631.	6.6	25